Patents - Global Data - Dimensions
Application
Daptomycin formulations
Applicants
- Xellia (Denmark)
[NORA names: Xellia; Private Research]
Abstract
The present disclosure relates to solid formulations of daptomycin that includes at least one branched chain aliphatic amino acid. The daptomycin solid formulations of the present disclosure exhibit improved reconstitution times. The present disclosure further relates to methods of making solid formulations of daptomycin according to the present disclosure.
Patent Family Records (10)
Daptomycin formulation
Xellia (Denmark), Xellia Pharmaceuticals ApS FUMIC BARBARA
2024, AU-2021227095-B2
DAPTOMYCIN FORMULATION
Xellia (Denmark), Xellia Pharmaceuticals ApS FUMIC BARBARA
2023, US-20230068866-A1
Daptomycin preparation
Xellia (Denmark), Xellia Pharmaceuticals ApS フミッチ、バルバラ
2023, JP-2023516957-A
DAPTOMYCIN FORMULATION
Xellia (Denmark), Xellia Pharmaceuticals ApS FUMIC BARBARA
2023, EP-4110303-A1
DAPTOMYCIN FORMULATION.
XELLIA PHARMACEUTICALS APS, Xellia (Denmark) FUMIC BARBARA
2022, MX-2022010378-A
Daptomycin formulations
Xellia (Denmark), Xellia Pharmaceuticals ApS FUMICI BARBARA
2022, CN-115038431-A
DAPTOMICIN FORMULATION.
XELLIA PHARMACEUTICALS APS, Xellia (Denmark) BARBARA FUMIC
2022, BR-112022015571-A2
Daptomycin formulation
Xellia (Denmark), Xellia Pharmaceuticals ApS FUMIC BARBARA
2022, AU-2021227095-A1
DAPTOMYCIN FORMULATION
XELLIA PHARMACEUTICALS APS, Xellia (Denmark) FUMIC BARBARA
2021, WO-2021170807-A1
DAPTOMYCIN FORMULATION WITH BRANCHED AIPHATIC AMINO ACID
Individual FUMIC BARBARA
2021, CA-3168727-A1